Zogenix Shares Plunge 52% on FDA Panel’s Turn-Down of Painkiller

A Food and Drug Administration panel voted not to recommend approval for a painkiller made by Zogenix (ZGNX), sending the drug maker’s shares down by more than half in early trading today.

ZGNX Chart

ZGNX data by YCharts

Reuters reported that the panel had concerns about the addictive nature of the class of painkillers, opioids, that includes the proposed Zogenix drug, Zohydro.

As reported, painkiller addiction in the U.S. is huge and rising.

For Zogenix, Reuters reported, the decision could be a huge blow unless overturned by the FDA itself: “Wall Street analysts say FDA approval could bring Zogenix up to $500 million in annual sales from Zohydro by 2019, or more than ten times the pharmaceutical company's expected 2012 annual revenue of $45.5 million.”

From the editors of YCharts.

Read more articles about: Company Analysis  

blog comments powered by Disqus
Advertisement

Search Articles

Subscribe to YCharts Analysis

Advertisement

{{root.upsell.info.feature_headline}}.
Upgrade to {{root.upsell.info.tier_name}}. Start Your YCharts Membership. Start your {{root.upsell.info.tier_name}} Membership

{{root.upsell.info.feature_description}}

{{root.upsell.info.is_upgrade ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{root.upsell.info.tier_name}} Member? Sign in here.